NCI must make a bigger investment in new cancer therapies and expand the clinical trials system that tests them, the institute’s Acting Director Douglas Lowy said in his remarks at the American Society of Clinical Oncology annual meeting June 4.
Fadlo Khuri, president of the American University of Beirut, was honored for his service as editor-in-chief of Cancer, a journal of the American Cancer Society, in a reception June 3 at the 2022 ASCO annual meeting.
The American Association for Cancer Research released its Cancer Disparities Progress Report 2022, the second AACR report on this topic.
Darrel P. Cohen was named chief medical officer of cell therapy at Athenex Inc. In this role, Cohen will lead the company’s clinical development, clinical operations, and regulatory affairs functions, replacing Kurt Gunter.
People with advanced cancer who communicated their symptoms weekly using an electronic survey had about a one-third better physical function and over a 15% better control of their symptoms compared to those who were evaluated less frequently via in-person clinical visits, according to findings from a multi-state study conducted at 52 community cancer clinics.
Researchers from the Parker Institute for Cancer Immunotherapy network identified certain patients with pancreatic cancer who may be more likely to benefit from combination treatment regimens consisting of immunotherapy and chemotherapy.
Positive data from a pivotal phase II/III trial for BCG-unresponsive non-muscle invasive bladder cancer carcinoma in situ (QUILT 3032) and phase II trial in advanced pancreatic cancer (QUILT 88) were announced at the 2022 ASCO annual meeting.
Data from the phase III PARADIGM clinical trial of Vectibix (panitumumab) in Japanese patients with previously untreated unresectable wild-type RAS metastatic colorectal cancer were featured during the plenary session of the 2022 ASCO annual meeting.
Racial and ethnic minorities diagnosed with advanced liver cancer have a lower chance of receiving immunotherapy, the most effective treatment for patients with the disease, according to a study led by Cedars-Sinai Cancer investigators.
Researchers at the American Cancer Society found that the number of women in the U.S. who reported having a recent (in the past year) breast cancer or cervical cancer screening dropped by 2.13 million (6%) and 4.47 million (11%) respectively in 2020 compared to 2018.
